Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
CARVYKTI is a BCMA-directed CAR-T therapy for RRMM, offering differentiated efficacy with substantial safety management requirements.
Zolbetuximab establishes a targeted first-line treatment option for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, supported by pivotal efficacy and safety evidence.
COBENFY represents a novel non-dopaminergic antipsychotic for schizophrenia, demonstrating consistent monotherapy efficacy with differentiated tolerability and selective clinical positioning.
177Lu-DOTATATE is a well-established, cost-effective targeted radioligand therapy positioned for SSTR-positive GEP-NETs requiring specialized, multidisciplinary care.
Daratumumab improves multiple myeloma outcomes across disease stages, with manageable toxicity, operational advantages in subcutaneous delivery, and expanding guideline-supported roles.
Semaglutide provides robust glycemic, weight, cardiovascular, and renal benefits in type 2 diabetes, with manageable risks requiring careful titration.
Osimertinib delivers substantial efficacy and central nervous system control across EGFR-mutant NSCLC settings, with manageable toxicity and evolving resistance-guided strategies.
Resmetirom, a hepatoselective partial THR-β agonist, improves MASH histologic and lipid endpoints, but warrants periodic safety monitoring and confirmation of long-term clinical outcomes.
This review summarizes the efficacy, safety profile, sequencing considerations, and evolving clinical role of Trodelvy in advanced breast cancer.
Enhertu demonstrates substantial efficacy across HER2-driven malignancies, with meaningful survival benefits but an important risk of interstitial lung disease requiring careful monitoring.
Apixaban provides effective, convenient anticoagulation across approved indications, lowering stroke and bleeding risk while requiring careful dosing, interactions, perioperative management.
Risankizumab shows strong multi-indication efficacy, favorable tolerability, and cross-specialty utility, though IBD use is limited by intravenous induction logistics.
Biktarvy offers durable, guideline-preferred HIV treatment with strong efficacy, a high resistance barrier, HBV activity, and manageable safety, interaction, and use limitations.
Adalimumab shows broad efficacy, established safety, and durable value across indications, while biosimilars and newer mechanisms reshape global adoption.
Tirzepatide delivers substantial, durable weight loss and cardiometabolic benefits with manageable gastrointestinal risks, though long-term safety and access remain important considerations.
Dupilumab inhibits IL-4/IL-13 signaling, demonstrating broad efficacy, acceptable safety, and biomarker-guided utility across multiple type 2 inflammatory diseases populations
Nivolumab, an anti-PD-1 monoclonal antibody, demonstrates durable survival benefits across multiple malignancies, with expanding regulatory approvals and biomarker-guided patient selection optimising its benefit-risk profile.
This review examines the clinical efficacy, safety, biomarker selection, and practical adoption considerations guiding pembrolizumab use across major oncology indications.
Improving outcomes in PDAC appears to depend not only on therapeutic innovation, but also on more consistent delivery of timely, biomarker-informed, multidisciplinary, and equitable care.
HCC management continues to be constrained by surveillance underutilization, delayed diagnosis, inconsistent multidisciplinary care, treatment heterogeneity, and regional disparities, highlighting the need for risk-stratified, systems-level implementation beyond guideline dissemination alone.